← All compounds
peptide56 listings
Tesamorelin
GHRH Analog
FDA-approved GHRH analog. Strong adipose research data.
Adipose researchGH research
/ research index
The research base
Research Maturity
★★★★☆
4/5 — Volume of studies
Evidence Strength
★★★★★
5/5 — Quality of evidence
Multiple Phase 3 trials. FDA approved for specific research applications.
/ mechanism of action
How it works
GHRH receptor agonist with longer half-life than CJC-1295.
/ research dosing
Common research protocols
Range
1-2 mg/day (FDA-approved dose is 2mg/day)
Frequency
Once daily, ideally before bed
Route
Subcutaneous abdomen
Cycle
Continuous use studied 26-52 weeks
Research notes
FDA-approved as Egrifta for HIV-related lipodystrophy at 2mg/day. Stable GHRH analog with longer half-life than sermorelin. Pre-bed dosing aligns with natural GH release. Often researched for visceral adipose effects.
References
FDA Egrifta labelPMID: 17890677 →
FOR RESEARCH USE ONLY. Doses listed are compiled from published research literature, FDA-approved drug labels, and well-documented research community practice. Not medical advice.
/ standalone use
As a solo compound
Strong standalone evidence. FDA-approved for solo use.
Common pairings
/ side effects
What to know
Generally well-tolerated.
/ timeline
Realistic expectations
8-12 weeks for body composition research outcomes
/ recommendation
Where to buy Tesamorelin
🏆Our pick for Tesamorelin
Modern Research Peptides
10mg · USA · Card / Crypto
- ✓Third-party tested (Janoshik)
- ✓COAs provided — Per-batch comprehensive
- ✓Within 6% of cheapest, higher verification tier
- ✓4.8★ community rating
Also solid
/ all listings
Full index, price per mg
Supplier
Trust Score
Size
Price
$/mg
Stock
Buy
FOR RESEARCH USE ONLY. Tesamorelin is intended for laboratory research and not for human consumption.